News | Heart Failure | February 07, 2017

Cancer Drug Could Double as a Weapon Against Heart Disease

UTSW researchers discover drug unexpectedly promotes regeneration of damaged heart tissue

UTSW, new cancer drug, heart failure, tissue repair

February 7, 2017 — A new anticancer agent in development promotes regeneration of damaged heart muscle — an unexpected research finding that may help prevent congestive heart failure in the future.

Many parts of the body, such as blood cells and the lining of the gut, continuously renew throughout life. Others, such as the heart, do not. Because of the heart’s inability to repair itself, damage caused by a heart attack causes permanent scarring that frequently results in heart failure.

For years, Lawrence Lum, Ph.D., associate professor of cell biology at University of Texas (UT) Southwestern Medical Center, has worked to develop a cancer drug targeting Wnt signaling molecules. These molecules are crucial for tissue regeneration, but also frequently contribute to cancer. Essential to the production of Wnt proteins in humans is the porcupine (Porcn) enzyme, so-named because fruit fly embryos lacking this gene resemble a porcupine. In testing the porcupine inhibitor researchers developed, they noted a curiosity.

“We saw many predictable adverse effects — in bone and hair, for example — but one surprise was that the number of dividing cardiomyocytes was slightly increased,” said Lum, senior author of the paper, and a member of UTSW’s Hamon Center for Regenerative Science and Medicine. “In addition to the intense interest in porcupine inhibitors as anticancer agents, this research shows that such agents could be useful in regenerative medicine.”

Based on their initial results, the researchers induced heart attacks in mice and then treated them with a porcupine inhibitor. Their hearts’ ability to pump blood improved by nearly twofold compared to untreated animals.

The study findings were published online in Proceedings of the National Academy of Sciences.

“Our lab has been studying heart repair for several years, and it was striking to see that administration of a Wnt inhibitor significantly improved heart function following a heart attack in mice,” said Rhonda Bassel-Duby, Ph.D., professor of molecular biology and associate director of the Hamon Center.

Importantly, in addition to the improved pumping ability of hearts in the mice, the researchers noticed a reduction in fibrosis, or scarring in the hearts. Collagen-laden scarring that occurs following a heart attack can cause the heart to inappropriately increase in size, and lead to heart failure.

“While fibrotic responses may be immediately beneficial, they can overwhelm the ability of the heart to regenerate in the long run. We think we have an agent that can temper this fibrotic response, thus improving wound healing of the heart,” said Lum, a Virginia Murchison Linthicum Scholar in Medical Research and associate director of basic research at the Harold C. Simmons Comprehensive Cancer Center.

Additionally, Lum said, preliminary experiments indicate that the porcupine inhibitor would only need to be used for a short time following a heart attack, suggesting that the unpleasant side effects typically caused by cancer drugs might be avoided.

“We hope to advance a Porcn inhibitor into clinical testing as a regenerative agent for heart disease within the next year,” Lum said.

For more information: www.pnas.org

References

Moon, J., Zhou, H., Zhang, L., Tan, W., et al. "Blockade to pathological remodeling of infarcted heart tissue using a porcupine antagonist," Proceedings of the National Academy of Sciences. Published online Jan. 31, 2017. doi:10.1073/pnas.1621346114

Related Content

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement
News | Heart Failure | November 02, 2018
In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the...
Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

CHF Solutions' Aquadex FlexFlow System

News | Heart Failure | November 01, 2018
November 1, 2018 — Daxor Corp.
NHLBI Pauses CONCERT-HF Heart Failure Trial
News | Heart Failure | October 29, 2018
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is pausing the...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018
October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S
Ohio State First in U.S. to Test Shunt Device for Heart Failure
News | Heart Failure | October 04, 2018
The Ohio State University Wexner Medical Center is first in the country to test a new medical device designed to help...
Mitral Regurgitation Volume Reduced at One Year in REDUCE FMR Trial
News | Heart Failure | September 28, 2018
Heart failure patients who received the Carillon Mitral Contour System in the REDUCE FMR clinical trial showed a...
Cardiac Dimensions Randomizes First Patient in CARILLON Trial of Mitral Contour System
News | Heart Failure | September 20, 2018
Cardiac Dimensions announced the company has randomized its first patient in the CARILLON Pivotal Trial.
Overlay Init